Cholesterol efflux is LXRα isoform-dependent in human macrophages

BMC Cardiovascular Disorders

Qian Zhang¹  Zhi Yuan Song¹  A Zhi Sha Ma² 

[1] Department of Cardiology, Southwest Hospital, The Third Military Medical University, Chongqing, China;Department of Cardiology, The fifth hospital of Chinese PLA, Yinchuan, China

关键词: Atherosclerosis;    ABC transporter;    siRNA;    Liver X receptor;    Reverse cholesterol transport;   

Others  :  1088490
DOI  :  10.1186/1471-2261-14-80

 received in 2014-02-21, accepted in 2014-06-26,  发布年份 2014

【 摘 要 】

Background

The nuclear receptor liver X receptor (LXR) has two isoforms: LXRα and LXRβ. LXR activation promotes cholesterol efflux in macrophages, but the relative importance of each LXR isoform in mediating cholesterol efflux remains elusive.

Methods

We evaluated the ability of different doses of LXRs agonist T0901317 to affect cholesterol efflux in human macrophages and its relationship with mRNA and protein levels of several well-characterized proteins involved in cholesterol efflux, including ABCA1, ABCG1, SR-BI, LXRβ and LXRα, using quantitative real-time PCR, Western blotting, and siRNA techniques.

Results

Here we show that LXRα rather than LXRβ sustains baseline cholesterol efflux in human blood-derived macrophages. Treatment of human macrophages with a non-isoform-specific LXR agonist T0901317 substantially increased HDL- and apoA-I-mediated cholesterol efflux, which was associated with increased mRNA and protein expression levels of ABCA1, ABCG1, SR-BI, LXRα and LXRβ. The siRNA- mediated silencing of LXRα, but not LXRβ significantly reduced the protein levels of ABCA1,ABCG1, and SR-BI as wellas HDL- and ApoA1-mediated cholesterol in human macrophages.

Conclusions

These findings imply that LXRα- rather than LXRβ- specific agonists may promote reverse cholesterol transport in humans.

【 授权许可】

   
2014 Ma et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
• [2]Bobryshev YV: Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006, 37:208-222.
• [3]Escolà-Gil JC, Rotllan N, Julve J, Blanco-Vaca F: In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis 2009, 206:321-327.
• [4]Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96:1221-1232.
• [5]Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ: LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995, 9:1033-1045.
• [6]Repa JJ, Mangelsdorf DJ: The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000, 16:459-481.
• [7]Kugimiya A, Takagi J, Uesugi M: Role of LXRs in control of lipogenesis. Tanpakushitsu Kakusan Koso 2007, 52(13 Suppl):1814-1815.
• [8]Maglich JM, Caravella JA, Lambert MH, Willson TM, Moore JT, Ramamurthy L: The first completed genome sequence froma teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Res 2003, 31:4051-4058.
• [9]Reschly EJ, Ai N, Welsh WJ, Ekins S, Hagey LR, Krasowski MD: Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol 2008, 110:83-94.
• [10]Prüfer K, Boudreaux J: Nuclear localization of liver X receptor alpha and beta is differentially regulated. J Cell Biochem 2007, 100:69-85.
• [11]Zelcer N, Tontonoz P: Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006, 116(3):607-614.
• [12]Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T: T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003, 536:6-11.
• [13]Peng D, Hiipakka RA, Reardon CA, Getz GS, Liao S: Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver x receptor agonist T0901317. Atherosclerosis 2009, 203(1):59-66.
• [14]Tang SL, Chen WJ, Yin K, Zhao GJ, Mo ZC, Lv YC, Tan , Ouyang XP, Yu XH, Kuang HJ, Jiang ZS, Fu YC, Tang CK: PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXR through the IGF-I-mediated signaling pathway. Atherosclerosis 2012, 222:344-354.
• [15]Tontonoz P, Margesdorf DJ: Liver X receptor signaling pathway in cardiovascular disease. Mol Endocrinol 2003, 17:985-993.
• [16]Gao M, Le B, Yongjie M, Dexi L: Concurrent Activation of Liver X Receptor and Peroxisome Proliferator-Activated Receptor Alpha Exacerbates Hepatic Steatosis in High Fat Diet-Induced Obese Mice. PLoS One 2013, 8(6):e65641.
• [17]Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ: An oxysterol signaling pathway by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
• [18]Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Björkhem I, Pettersson S, Gustafsson JA: Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J Clin Invest 2001, 107:565-573.
• [19]Ji A, Meyer JM, Cai L, Akinmusire A, de Beer MC, Webb NR, van der Westhuyzen DR: Scavenger receptor SR-BI in macrophage lipid metabolism. Atherosclerosis 2011, 217(1):106-112.
• [20]Ishibashi M, Filomenko R, Rébé C, Chevriaux A, Varin A, Derangère V, Gambert P, Lagrost L, Masson D: Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation. Biochem Pharmacol 2013, 86(1):122-129.